Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 7091186 None

Patent 7091186 was granted and assigned to Seagen on August, 2006 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Seagen
Seagen
Date Filed
September 24, 2001
Date of Patent
August 15, 2006
Patent Application Number
09963103
Patent Citations Received
‌
US Patent 12134610 Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
0
‌
US Patent 11944689 Drug conjugates with self-stabilizing linkers having improved physiochemical properties
0
‌
US Patent 12016842 Methods of using anti-CD79b immunoconjugates
0
‌
US Patent 12129306 Antibodies binding to STEAP-1
0
‌
US Patent 11685790 Antibodies binding to STEAP-1
0
‌
US Patent 11788066 Antibody conjugates and methods of making and using the same
‌
US Patent 11866496 Humanized anti-CD79B antibodies and immunoconjugates and methods of use
0
‌
US Patent 11911483 Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
0
‌
US Patent 11931414 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
0
‌
US Patent 11932650 Potent agelastatin derivatives as modulators for cancer invasion and metastasis
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7091186
Patent Primary Examiner
‌
David Lukton

Find more entities like US Patent 7091186 None

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.